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Abstract
Background: Immunization policymakers at global and local levels need to establish priorities among new
vaccines competing for limited resources. However, comparison of the potential impact of single vaccination
programs is challenging, primarily due to the limited number of vaccine analyses as well as their differing analytic
approaches and reporting formats. The purpose of this study is to provide early insight into how the comparative
impact of different new vaccines could be assessed in resource-poor settings with respect to affordability,
cost-effectiveness, and distributional equity.
Methods: We compared the health, economic, and financial consequences of introducing the two vaccines in 72
GAVI-eligible countries using a number of different outcome measures to evaluate affordability, cost-effectiveness,
and distributional equity. We use simple static models to standardize the analytic framework and improve
comparability between the two new vaccines. These simple models were validated by leveraging previously
developed, more complex models for rotavirus and human papillomavirus (HPV).
Results: With 70% coverage of a single-age cohort of infants and pre-adolescent girls, the lives saved with
rotavirus (~274,000) and HPV vaccines (~286,000) are similar, although the timing of averted mortality differs;
rotavirus-attributable deaths occur in close proximity to infection, while HPV-related cancer deaths occur largely
after age 30. Deaths averted per 1000 vaccinated are 5.2 (rotavirus) and 12.6 (HPV). Disability-adjusted life years
(DALYs) averted were ~7.15 million (rotavirus) and ~1.30 million (HPV), reflecting the greater influence of
discounting on the latter, given the lagtime between vaccination and averted cancer. In most countries (68 for
rotavirus and 66 for HPV, at the cost of I$25 per vaccinated individual) the incremental cost per DALY averted was
lower than each country’s GDP per capita. Financial resources required for vaccination with rotavirus are higher
than with HPV since both genders are vaccinated.
Conclusions: While lifesaving benefits of rotavirus and HPV vaccines will be realized at different times, the number
of lives saved over each target populations’ lifetimes will be similar. Model-based analyses that use a standardized
analytic approach and generate comparable outputs can enrich the priority-setting dialogue. Although new
vaccines may be deemed cost-effective, other factors including affordability and distributional equity need to be
considered in different settings. We caution that for priority setting in an individual country, more rigorous
comparisons should be performed, using more comprehensive models and considering all relevant vaccines and
delivery strategies.
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Several new vaccines have recently become available,
including those against rotavirus, human papillomavirus
(HPV), and pneumococcus. To set new policies for opti-
mum use of these vaccines in different settings, partici-
pating entities including international agencies (e.g.,
World Health Organization [WHO]), domestic policy-
makers, financing coordination mechanisms (e.g., GAVI
Alliance), and donors [1,2] will need new information
on which to base their decisions.
Unfortunately, given the complexity of many vaccine-
preventable diseases [3], the impact and inevitable trade-
offs associated with a particular vaccine program are
never fully known until well after implementation. To
help resolve this uncertainty for policymakers, a decision
analytic approach using a disease-specific model can be
used to organize, synthesize and integrate the available
clinical, epidemiologic, and economic information and
to estimate the cost-effectiveness of a prospective vac-
cine program [4,5]. Furthermore, such model-based ana-
lyses can also be useful for generating other outcomes
such as intermediate (e.g., infections averted and cases
averted) and long-term outcomes (e.g., deaths prevented
and disability-adjusted life years [DALYs] averted) as
well as the timing of those outcomes (e.g., immediate,
within a few years, or decades later). Finally, a model-
based analysis can help to identify the more influential
determinants of a vaccine’s expected impact and value
in a given setting.
Recently, economic evaluation studies using a model-
ing approach have reported that many of the new vac-
cines would substantially reduce disease-specific
mortality and provide good value for money in low- to
middle-income country settings [6-9]. However, these
vaccines also tend to be far more expensive than the
traditional childhood vaccines previously introduced
into these countries, many of which now face growing
populations and unprecedented budget constraints. It is
in this context that immunization policy makers at both
global and local levels need to establish priorities among
the new vaccines competing for limited resources
[10,11]. Even for countries wishing to adopt multiple
new vaccines, there are inevitable questions about which
programs should be implemented earlier and whether
some should be implemented more aggressively than
others. Such priority decisions would entail various con-
siderations (e.g., cost-effectiveness, affordability, and
equity), and there has been an increasing attention paid
to how best to achieve a balance between these consid-
erations [12,13].
However, comprehensive comparison of prospective vac-
cine programs in low- to middle-income country settings
is difficult. There have been few economic evaluations of
new vaccines in resource-poor settings, for which impor-
tant data is often lacking. Additionally, the cost-effectiveness
profiles derived for individual vaccines from separate stu-
dies make for problematic comparison, as the analyses
use different data sources and assumptions. Furthermore,
independent analyses conducted for a single vaccine are
often presented in different formats making it more chal-
lenging to compare results.
Nevertheless, since policymakers will likely have to
make early and comprehensive priority decisions in the
context of incomplete information, even a preliminary
comparison based on the available data would be useful
to inform deliberative dialogue among stakeholders [14].
Indeed, there recently has been an increasing demand
for this type of information among international agen-
cies and immunization financing mechanisms.
Motivated to provide early insight into how the com-
parative impact of different new vaccines could be
assessed across different resource-poor settings (where
most benefits from the vaccines would be realized), we
leverage our previously conducted analyses for rotavirus
and HPV (conducted for each disease separately)
[6,15-19]. Given that new vaccine prices are often
unknown at the early stages of vaccine arrival, and that
data on country-specific program delivery costs are
highly uncertain and rarely available in resource-poor
settings, we take a composite cost approach that
assumes the same level of plausible, collective program
costs across the countries for each of the two vaccines.
We thus compare the health, economic, and financial
impact of introducing these two vaccines in 72 GAVI
support-eligible low-income countries, with a primary
focus on relative disease burden. In doing so, we stan-
dardize a simple modeling approach and analytic frame-
work in order to facilitate comparison. We also identify
and highlight methodologic challenges and influential
uncertainties that should be considered as discussions
about vaccine prioritization unfold.
A brief summary of the key features of the diseases
caused by the two pathogens–rotavirus and HPV–and
the characteristics of the two new vaccines follows:
Rotavirus
Rotavirus is the major cause of severe, dehydrating diar-
rhea among children under 5 years of age [20,21]. Rota-
virus infection is responsible for more than 2 million
hospitalizations and approximately 527,000 deaths
annually on a global level. While almost all children
experience rotavirus infection by the age 5 in both
developing and developed countries, the burden of dis-
ease is disproportionately high in developing countries,
with ~90% of rotavirus associated deaths occurring in
developing nations [20]. Human rotavirus comes in
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independent combination of two different groups of
proteins, G and P. The most prevalent serotype world-
wide is G1P[8], and approximately 90% of human rota-
virus infections are caused by one of five types of
strains: G1P[8], G2P[4], G3P[8], G4P[8], and G9P[8]
[22]. The distribution of serotypes is reported to vary
across countries and even local regions or over time in
the same country [23]. Recently two new rotavirus vac-
cines (Rotarix
® and RotaTeq
®) have been licensed. Rota-
virus vaccines have been assigned a high priority on the
global vaccine agenda, given their potential to contribute
to improving general development as well as childhood
health in developing countries. Based on new evidence
on vaccine safety and efficacy from recent clinical trials
in African settings [24], the WHO has released a global
recommendation that all countries include infant rota-
virus vaccination in their national immunization pro-
grams, and the GAVI Alliance has promised to provide
financial support for rotavirus vaccination programs to
developing countries.
HPV
Cervical cancer is the third most common cancer in
women globally, and the most common cancer in women
in Eastern Africa, South-Central Asia, and Melanesia
[25]. Globally, more than 500,000 cases of cervical cancer
and ~270,000 deaths occur each year. Cervical cancer is
also a disease of inequity, with ~80% of deaths occurring
in developing countries [26]. HPV is the primary cause of
cervical cancer, and HPV types 16 and 18 are known to
cause ~70% of cervical cancer [27]. Worldwide, the eight
most common genotypes (HPV 16, 18, 45, 31, 33, 52, 58,
and 35) account for 90% of cases of cervical cancer [28].
Regional variations in cervical cancer incidence are due
to differences in underlying prevalence of high-risk HPV
types as well as marked differences in the availability and
effectiveness of cervical screening and treatment pro-
grams. Recently, two new vaccines against HPV 16 and
18 (Gardasil
® and Cervarix
®) have been made available.
Like rotavirus vaccines, HPV vaccines have received a
high priority and there have been global efforts to accel-
erate the introduction of the vaccines in developing
countries. HPV vaccines are included on the list of the
United Nations prequalified vaccines [29], and the GAVI
Alliance has declared HPV vaccines as one of the priori-
ties for GAVI countries [30].
Figure 1 shows the relative magnitude of the disease
burden associated with rotavirus versus HPV infection.
Methods
Previous studies for HPV
We have previously described our series of cervical can-
cer models that include an individual-based stochastic
model to simulate cervical carcinogenesis associated
with all high-risk HPV types and a dynamic model to
simulate sexual transmission of HPV 16 and 18 infec-
tions between males and females, which have been
applied to multiple settings [15,31-36]. We used a likeli-
hood-based approach to calibrate the stochastic models
to empirical data, such as age-specific prevalence of
HPV, age-specific incidence of cervical cancer, and HPV
type distribution in normal females, cancer precursors,
and cervical cancer [31]. Our empirically-calibrated
models included 8 GAVI-eligible countries (2 countries
in Asia, India and Vietnam [Hanoi and Ho Chi Minh
City], and 6 countries in Africa [Zimbabwe, Tanzania,
Nigeria, Kenya, Uganda, and Mozambique]) and 7 coun-
tries in Latin America and the Caribbean (Brazil, Argen-
tina, Chile, Colombia, Costa Rica, Mexico, and Peru).
Recognizing that the data required for such complex
models are not available for all 72 GAVI-eligible coun-
tries, we constructed a companion Excel-based model
(Microsoft
® Excel 2003 and Visual Basic for Applica-
tions 6.3). The companion model was structured as a
static cohort simulation model [6,18,19,37] (Figure 2,
Upper Panel), and employed simplifying assumptions
relying on insights from the more complex model (e.g.,
the plausible ranges of parameters and the effects
of simplified natural history on model outcomes)
[6,18,19]. We leveraged our empirically-calibrated
models [15,33,34] to validate the companion model by
comparing projected model outcomes for selected
countries to those obtained using the companion
model.
Using the validated companion model, we synthesized
population-level data on demographic structure, country-
specific disease burden (incidence of cervical cancer),
medical utilization patterns, and costs (expressed in 2005
international dollars [I$]) in order to estimate the health
and economic consequences associated with HPV vaccina-
tion in the GAVI countries [6]. The sources of the key
data are presented in Table 1[6,15,18,19,28,38-55]. Because
the vaccine prices and vaccination program costs in
GAVI-eligible countries are not yet known, we used a
composite cost approach, assuming I$10, I$25, or I$50 for
delivering a full course of HPV vaccines, based on the
assumed per-dose price of the vaccines (see previous stu-
dies [6,15,18,19,32-34] for details). The model followed a
single 2007 cohort of 9-year-old girls (i.e., pre-adolescent
girls) over their lifetime. The model projected clinical out-
comes including prevented cases of cervical cancer and
cervical cancer deaths, years of life saved, and DALYs
averted. The cost-effectiveness was measured in incremen-
tal cost per DALY averted from the (limited) societal per-
spective, and both future costs and disability-adjusted and
unadjusted life years were discounted at 3% annually
[44,55,56].
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influence of both uncertain parameters and assumptions
on results. In addition to cost-effectiveness, in order to
provide policy makers with more practical information
on financial forecasting and the overall absolute reduc-
tion in disease burden over a longer term, we extended
the base case analysis by adding different roll-out sce-
narios over a 10-year period (2010-2019), varying the
year of vaccine introduction, maximum achievable cov-
erage rate, and year to full coverage across countries [6].
Previous studies for rotavirus
For rotavirus vaccines, we took a similar path. We first
developed a state-transition model of rotavirus infection,
which captures detailed natural history such as the age-
specific incidence, probability of asymptomatic cases, rate
of reinfection, correlation between strength of natural
immunity and the total number of previous infections,
and waning of vaccine efficacy [16]. We used the model
to re-evaluate the cost-effectiveness of rotavirus vaccines
in Vietnam [16]. Given the lack of data standardized for
the 72 GAVI countries, we constructed a companion
Excel-based model (Figure 2, Lower Panel) using analo-
gous methods to those used for HPV (e.g., the use of a
composite cost approach), and similarly validated the
model by comparing the model predicted outcomes with
those from more complex state-transition models [17].
We then performed similar analyses to evaluate the cost-
effectiveness of rotavirus vaccines and to project reduc-
tion in burden of disease and financial requirements
associated with rotavirus vaccination using a variety of
scale-up scenarios. Details of model input, assumptions,
and results have been described elsewhere [17].
Comparative evaluation
While the two companion models for HPV and rota-
virus [6,17] share similar model structure and many
other features, not all the analytical choices are the
same, as the models were developed in independent stu-
dies performed at different times. For example, the two
previous studies [6,17] were based on hypothetical
cohorts in different calendar years and had different
scopes of the costs considered in the base-case analyses.
Accordingly, to comparatively evaluate the health and
economic impact of the two new vaccines (HPV and
rotavirus), we further standardized on some analytic
choices and scope of the costs, but kept the same model
inputs and assumptions as described in the previously
published articles [6,17]. Table 1 summarizes the metho-
dological choices, model structure, and key assumptions
of the two simulations as well as sources of the key
data. For a simulation estimating the vaccines’ cost-
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Figure 1 Joint distribution of disease burden caused by rotavirus versus HPV in the 72 GAVI-eligible countries.
Kim et al. BMC Infectious Diseases 2011, 11:174
http://www.biomedcentral.com/1471-2334/11/174
Page 4 of 17effectiveness, we followed a single cohort of girls aged 9
in 2010 for HPV and a birth cohort born in the same
year for rotavirus, assuming two different levels of com-
posite program costs, I$10 and I$25 per vaccinated indi-
vidual. Because we have previously forecasted financial
requirements for the two vaccines separately, using
a range of alternative uptake and scale-up scenarios
that varied by country, we conduct only a comparative
analysis here that assumes both vaccines achieve the
same coverage in their respective target populations.
Figure 2 Schematic of the companion models.
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Page 5 of 17Table 1 Comparison of the two analyses using an Excel-based model: Rotavirus versus HPV [6,15,18,19,38–55]
Main features/
Assumptions
Rotavirus HPV
Study design overview
Country/Region 72 GAVI-eligible countries Same
Study type Cost-effectiveness analysis Same
Perspective (Limited) societal perspective Same
Currency 2005 international dollars (I$) Same
Base year for discounting 2009 Same
Year of intervention 2010 Same
Primary outcome measure ICER (I$/DALY averted) Same
Discount rate (base-case) Health outcome: 3%, Cost: 3% Same
Model type and structure
Model type Static cohort model (implicitly based on a decision tree) Same
Model outcomes Costs
Cases of rotavirus-associated deaths, hospitalizations, and outpatient
visits
Life years saved
DALYs averted
Costs
Cases of cervical cancer and cervical cancer
deaths
Life years saved
DALYs averted
Time horizon (span) 5 years (ages 0-4) Lifetime (ages 9-99)
Software for programming Microsoft Excel and VBA Same
Assumptions on intervention and vaccine efficacy
Vaccine type Rotarix
® or Rotateq
®
(non-distinguished)
Gardasil
® or Cervarix
®
(non-distinguished)
Strategies Routine versus no vaccination Same
Target population Infants 9-year-old girls
Vaccination schedule 2,4,and 6 months of age The second and third doses administered 1 and
6 months after the first dose
Coverage (base-case) 70% Same
Vaccine efficacy (serotype-
specific)
G1P[8]: 87%
G3P[8]: 90%
G4P[8]: 93%
G9P[8]: 84%
G2P[4], other combination:71%
100% against cervical cancer caused by HPV
16/18
Vaccine efficacy adjusted for
serotype distribution
Yes Yes
Assumptions on natural
history
Serotype distribution Country-specific Same
Duration of vaccine
immunity
5 years (ages 0-4) Lifetime (ages 9-99)
Waning of vaccine-acquired
immunity
No No
Natural immunity considered No No
Herd immunity considered No No
Assumptions on resource
use
Range of costs included Direct medical costs (composite program costs and medical
treatment costs)
Same
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Page 6 of 17This analysis is not intended to guide budgetary plan-
ning as a flat 70% coverage rate is not realistic; rather, it
is intended to simply provide insight into the compara-
tive magnitude of resources that would be required
under favorable circumstances for each vaccine.
Model validation
As previously stated, both companion models for HPV
and rotavirus have been corroborated by comparing the
model-projected outcomes with those obtained using
more complex (stochastic or state-transition) models for
selected low- to middle-income countries [6,17]. In
doing so, we adjusted the key parameter assumptions of
the companion models to closely match those from the
more complex models. However, given that those com-
plex models used in the corroboration exercises are also
static and therefore inherently limited in capturing
indirect herd immunity effects, we also attempted to
compare the outcomes obtained using our static models
with those from published dynamic models for rotavirus
[57-59] and HPV [32,35,36,60-63]. Additional file 1
Table S1 presents details of the process using examples
of Vietnam, Kyrgyzstan, and Brazil.
Results
Model validation
The corroboration exercises showed that, for both rota-
virus and HPV, our results using the companion models
are consistent with those obtained from more compre-
hensive static models (Additional file 1 Table S1). The
comparison with a dynamic model of rotavirus devel-
oped in Kyrgyzstan [58] showed that our static model
projected slightly fewer health benefits (in terms of lives
saved and DALYs averted) presumably because our sta-
tic model cannot capture herd immunity effects, but
that the outcomes would be of the same order of mag-
nitude as those from the published dynamic model [42].
Similarly, for HPV, when we compared our static model
with a published dynamic model [32], the incremental
cost-effectiveness ratios (ICERs) from our static model
were somewhat higher compared to those from the
dynamic model over the ranges of program costs
Table 1 Comparison of the two analyses using an Excel-based model: Rotavirus versus HPV [6,15,18,19,38–55] (Continued)
Working definition and
description of composite
program costs
A composite vaccination program cost was defined to be a total
cost per vaccinated individual for delivering a full course of
vaccines, and was assumed to include the following cost items:
vaccine purchase, vaccine wastage, freight and insurance,
administrative cost, immunization support (including cold chain,
training, and operational costs), and other programmatic costs
(including surveillance and monitoring and social mobilization).
For a composite cost of I$10 and I$25, vaccine purchase cost was
US$4.5 (3 doses at US$.50 each) and US$15 (3 doses at US$5 each),
respectively.
Same
Levels of composite costs
used in a comparative
simulation
I$10 and I$25 Same
Medical utilization for
treatment
1) Rotavirus gastroenteritis requiring outpatient visit: one time
outpatient clinic visit
2) Rotavirus gastroenteritis requiring hospitalization: one time
outpatient visit plus a 3-day admission
3) Rotavirus gastroenteritis leading to deaths: one time outpatient
visit plus a 3-day admission
Stage-specific treatment costs assume
diagnostic workup, inpatient and outpatient
visits, follow-up [6,15]
Access to care 100% for the base-case
(varied in a sensitivity analysis)
Same
Sources of key data
Population prospect UN Population Prospect, The 2006 Revision [38] Same
Life expectancy WHO life tables (year 2006) [39] Same
Incidence (rotavirus-
associated deaths or cervical
cancer)
WHO estimates [40]
Published literature [20,21]
1) GLOBOCAN 2002 [41]
2) Cancer incidence in five continents (CI5C),
vol. I-VIII [42]
3) Cancer in Africa [43]
Treatment cost data WHO-CHOICE [44] WHO-CHOICE [44]
Published literature [6,15,18,19]
Serotype distribution Published literature [45-54] Published literature [28]
Disability weights Global Burden of Diseases 1990 [55] Same
ICER = incremental cost-effectiveness ratio, DALY = disability-adjusted life year.
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Page 7 of 17examined (I$25-I$400) (as expected), but the values
were of the same order of magnitude as those from the
dynamic model (Additional file 1 Table S1). This sug-
gests that our companion models would yield reasonably
consistent results compared with those that might be
obtained should a dynamic model be used.
Health outcomes
Vaccinating an entire single age cohort of infants and
pre-adolescent girls in the 72 GAVI-eligible countries
would amount to vaccinating approximately 75.8 million
infants of both genders for rotavirus and 32.5 million 9-
year-old girls for HPV (Table 2). Assuming 70% cover-
age, the numbers of vaccinated infants and pre-adoles-
cent girls were 53.0 million and 22.7 million for
rotavirus and HPV, respectively.
Model-projected health outcomes resulting from
simulating a single age cohort address the question,
“what outcomes would be expected if we vaccinated
70% of a single age group of infants and 70% of a single
age group of pre-adolescent girls (e.g., all 11-year-olds
today) - what outcomes would we expect if we tracked
the futures of these infants and girls over their respec-
tive lifetimes?” We found that, under the base-case
assumptions, rotavirus vaccines would prevent ~10.4
million outpatient visits, ~1.3 million hospital admis-
sions, and ~274,000 cases of rotavirus-associated deaths
among the vaccinated cohorts in GAVI countries over a
5-year time horizon. HPV vaccines would prevent
~360,000 cases of cervical cancer and ~286,000 cases of
cervical cancer-associated deaths among the cohort fol-
lowed for its lifetime. Assuming 70% coverage, the num-
ber of lives saved per 1,000 vaccinated individuals would
be about 5.2 for rotavirus vaccines versus 12.6 for HPV
vaccines (Table 2). Additional file 1 Table S2 presents
details of the country-specific health outcomes for each
of the GAVI countries.
Without discounting future health outcomes (as gen-
erally is recommended in a cost-effectiveness analysis),
years of life saved were ~15.74 and ~6.03 million for
rotavirus and HPV vaccines, respectively. The corre-
sponding figures for DALYs averted (without age-
weighting) were ~15.77 million for rotavirus and ~6.19
million for HPV vaccines. When we assumed 3% dis-
count rate for the future health outcomes, DALYs
averted were significantly reduced to ~7.15 million for
rotavirus and ~1.30 million for HPV vaccines. Note that
our base-case analyses calculated DALYs without age
weighting (i.e., with a uniform age weight). When we
weighted DALYs by age using the standard methods by
the Global Burden of Diseases (GBD) study [38], for
rotavirus vaccination, the undiscounted and discounted
(3%) numbers of DALYs averted increased to ~18.92
million and ~8.12 million, respectively. For HPV
vaccines, the corresponding figures decreased to ~4.85
million and ~1.15 million, respectively (Table 2).
Figure 3 presents the distribution of the averted death
burden in the GAVI-eligible countries for each of the
two vaccines by region. The upper panel shows that as a
result of rotavirus vaccination in the 72 GAVI countries,
~54% of the deaths averted would be in African settings
a n dj u s tu n d e rat h i r do ft h ed e a t h sa v e r t e dw o u l db ei n
South Asian settings. The lower panel shows that as a
result of HPV 16,18 vaccination in the 72 GAVI coun-
tries, ~57% of the deaths averted would be in South
Asian settings and just under a third of deaths averted
Table 2 Health outcomes of rotavirus versus HPV
vaccination among the 72 GAVI-eligible countries
(following a single cohort)
Health outcome measures Rotavirus HPV
Target population (year 2010) 75,761,613 32,453,017
Number vaccinated 53,033,129 22,717,112
Number of lives saved per 1000 vaccinated 5.2 12.6
Deaths averted (r = 0%) 273,855 285,921
Deaths averted by region (r = 0%)
(% of total)
AFR D, E 148,541
(54%)
89,524
(31%)
AMR A, B, D 1,808 (1%) 6,651 (2%)
EMR D 30,238
(11%)
12,611
(4%)
EUR B, C 3,257 (1%) 3,554 (1%)
SEAR B, D 85,579
(31%)
161,724
(57%)
WPR B 4,432 (2%) 11,857
(4%)
Years of life saved (r = 0%) 15,740,674 6,030,585
Years of life saved (r = 3%) 7,121,323 1,266,029
DALYs averted (r = 0%, uniform age weight) 15,767,404 6,191,573
DALYs averted (r = 3%, uniform age weight)* 7,146,859 1,304,426
DALYs averted by region (r = 3%, uniform
age-weight) (% of total)
AFR D, E 3,748,499
(52%)
436,230
(33%)
AMR A, B, D 50,093
(1%)
34,160
(3%)
EMR D 784,703
(11%)
55,724
(4%)
EUR B, C 90,541
(1%)
21,296
(2%)
SEAR B, D 2,350,198
(33%)
707,996
(54%)
WPR B 122,825
(2%)
49,020
(4%)
DALYs averted (r = 0%, non-uniform age
weight)
18,920,531 4,847,082
DALYs averted (r = 3%, non-uniform age
weight)
8,121,119 1,148,295
r = discount rate, DALY = Disability-adjusted life year.
* Base-case
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Page 8 of 17would be in African settings. Additional file 1 Figure S1
presents the age-distribution of the averted death burden
projected. While the health benefits of rotavirus vaccina-
tion apply to children under age 5, the majority of the
health benefits from HPV vaccination is realized in adult-
hood and span across decades rather than single years.
Cost-effectiveness analysis: base-case results
Figure 4 presents the cost-effectiveness analysis results
of the two new vaccines for two different composite
vaccination program costs, I$10 and I$25. Except for
three outlier countries (Cuba, Moldova, and Ukraine)
cost-effectiveness profiles of the two vaccines were very
similar. In Cuba, Moldova, and Ukraine (not shown in
Figure 4), ICERs of rotavirus vaccines are relatively high
(I$28,480, I$12,190, and I$4,530 per DALY averted for
C u b a ,U k r a i n e ,a n dM o l d o v a ,r e s p e c t i v e l y ,a s s u m i n gI
$25 per vaccinated child) presumably due to the
relatively low rotavirus disease burden (approximately 1,
2, and 5 rotavirus deaths per 100,000 children aged less
than 5 for Cuba, Ukraine, and Moldova, respectively).
For all other GAVI-eligible countries, at a cost of I$10
per vaccinated person (child or girl), for both rotavirus
and HPV vaccines, in more than 60 of the 72 countries,
either vaccination program was cost-saving or the cost per
DALY averted was less than I$200 (which is the lowest
2007 GDP per capita expressed in 2005 I$ among the 72
GAVI countries). At a cost of I$25 per vaccinated person,
the ICERs were higher, although still very attractive; using
the WHO’s cost-effectiveness threshold based on GDP per
capita [56], rotavirus vaccines would be considered cost-
saving or very cost-effective in 71 of 72 countries at a cost
per child of I$10 and very cost-effective in 68 of 72 coun-
tries at a cost per child of I$25. HPV vaccines would be
considered very cost-effective in 71 and 66 countries at a
cost of I$10 and I$25 per vaccinated girl, respectively.
Additional file 1 Table S3 presents details of the country-
specific cost-effectiveness results for each of the GAVI
countries. Additional file 1 Figure S2 shows the country-
specific ICERs categorized by region, for two composite
costs for each vaccine, I$10 and I$25. In general, the
ICERs for rotavirus vaccine at both costs are similar for
countries within the AFRO-D and AFRO-E regions. There
is greater variation in country-specific ICERs for HPV vac-
cines within all regions, including AFRO-D and AFRO-E.
Insight into the financial resources needed
The comparison of financial resources required for each
vaccine, holding coverage and cost constant, is intended
to only provide insight into the comparative magnitude
of resources that would be required under favorable cir-
cumstances for each vaccine. Additional file 1 Table S4
presents the financial requirements for the first decade
associated with introduction of each of the two new vac-
cines into GAVI countries, assuming a flat 70% coverage
over a 10-year period (2010-2019). Note that the esti-
mates of financial resources are based on the program
cost per individual of I$25 but are presented in US dol-
lars by converting the non-tradable portion of the com-
posite costs to 2005 US dollars, since budgets are
typically expressed in US dollars (or local currencies)
rather than international dollars [44]. The results show
that a 10-year rotavirus program would vaccinate ~537
million infants, requiring approximately US$11 billion to
reach 70% of eligible infants, while a similar program
for HPV would require ~US$4.9 billion to vaccinate
~237 million girls.
Sensitivity analysis
Table 3 presents selected results of a comprehensive
deterministic sensitivity analysis. Part (a) presents, using
a representative example of India, selected results of
Rotavirus
AFR D, 26.6%
AFR E, 27.7%
AMR, 0.7%
EMR, 11.0%
EUR, 1.2%
SEAR, 31.2%
WPR, 1.6%
AFR D AFR E AMR EMR EUR SEAR WPR
HPV
AFR D, 9.9%
AFR E, 21.4%
AMR, 2.3%
EMR, 4.4%
EUR, 1.2%
SEAR, 56.6%
WPR, 4.1%
Figure 3 Regional distribution of averted rotavirus-associated
and cervical cancer deaths in the 72 GAVI-eligible countries.
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Page 9 of 17univariate sensitivity analysis for a single country. For
rotavirus vaccines, results (in terms of ICERs) were
most sensitive to vaccination cost per child, discount
rate, rotavirus disease mortality, and vaccine efficacy.
For HPV vaccines, the most influential parameters
included vaccination cost per vaccinated girl, discount
rate, cervical cancer incidence, proportion of deaths
among incident cervical cancer cases, and vaccine effi-
cacy. For both vaccines, results were moderately sensi-
tive to treatment costs. Part (b) of the same table shows
how collective model outcomes for the GAVI-eligible
countries vary as the choice of discount rate and/or type
of age weight for DALY calculation are varied, for each
of the two vaccines. As also described in Table 2 health
outcomes in the forms of life years saved or DALYs
averted were more sensitive to discount rate than to the
choice of age weight. Finally, part (c) presents results of
scenario analysis (or multi-way sensitivity analysis), in
which vaccination costs, vaccine efficacy level, and mor-
tality rates were simultaneously varied, in the form of
numbers of countries that belong to each of the four
cost-effectiveness profile categories (i.e., cost-saving,
very cost-effective, cost-effective, and non-cost-effective)
defined by the WHO criteria [56] based on per capita
GDP. The results show that while the absolute numbers
of countries that belong to each category vary widely
depending on the combinations of the parameter values
assumed, the relative cost-effectiveness profiles between
the two vaccines (i.e., the distribution of the numbers of
countries that belong to each category for each vaccine)
did not vary remarkably.
Discussion
Our findings show that the number of lives saved in a
head-to-head comparison of a single-age cohort of
infants and pre-adolescent girls, with the rotavirus and
HPV vaccines, respectively, in the GAVI countries are
very similar even though the two vaccines target differ-
ent populations in terms of size and gender, and even
though the diseases the vaccines target have different
epidemiological features. The target population for rota-
virus vaccines is approximately twice as large as the tar-
get population for HPV vaccines (~76 million versus
~32 million for a single cohort) since the former
includes both genders while the latter only includes
g i r l s .H o w e v e r ,t h ea b s o l u t en u m b e ro fd e a t h sa v e r t e d
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Page 10 of 17Table 3 Selected results of sensitivity analysis
Parameters/Assumptions varied Outcome measures Rotavirus HPV
Part (a): One-way sensitivity analysis (Results for a single country, using India as a representative example)
Vaccination cost per individual ICER (I$/DALY averted)
I$5 16 saving
I$25 (base-case) 212 293
I$50 457 710
Incidence of rotavirus deaths ICER (I$/DALY averted)
80% of base-case 273 NA
100% (base-case) 212 NA
120% of base-case 171 NA
Incidence of cervical cancer ICER (I$/DALY averted)
80% of base-case NA 429
100% (base-case) NA 293
120% of base-case NA 203
Ratio of hospitalization to deaths associated with rotavirus ICER (I$/DALY averted)
80% of base-case 215 NA
100% (base-case) 212 NA
120% of base-case 209 NA
Proportion of deaths among incident cervical cancer
cases
ICER (I$/DALY averted)
50% NA 460
80% (base-case) NA 293
90% NA 261
Vaccine efficacy ICER (I$/DALY averted)
80% of base-case 273 397
base-case 212 293
120% of base-case 171 NA
Discount rate ICER (I$/DALY averted)
0% 92 saving
3% (base-case) 212 293
6% 377 1,609
Treatment costs ICER (I$/DALY averted)
75% of base-case 220 324
100% (base-case) 212 293
125% of base-case 204 262
Part (b): One-way/Two-way sensitivity analysis (Aggregated results across the GAVI-eligible countries)
Discount rate Years of life saved
r=0 % 15,740,674 6,030,585
r = 3% (base-case) 7,121,323 1,266,029
r=6 % 4,025,413 323,398
Discount rate Total incremental costs, I$
r=0 % 1,137,130,971 66,938,177
r = 3% (base-case) 1,106,950,990 422,123,822
r=6 % 1,078,274,716 494,334,220
[Discount rate, type of age weight] DALYs averted
[r = 0%, K = 0] 15,767,404 6,191,573
[r = 3%, K = 0] (base-case) 7,146,859 1,304,426
[r = 0%, K = 1] 18,920,531 4,847,082
[r = 3%, K = 1] 8,121,119 1,148,295
[Discount rate, type of age weight] No. of countries that belong to each of the cost-
effectiveness categories below (at the cost of I$25 per
vaccinated individual): [cost-saving, very cost-effective, cost-
effective, non-cost-effective]
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Page 11 of 17within each age cohort over their lifetime is slightly lower
for rotavirus vaccines than for HPV vaccines (~274,000
versus ~286,000); partly, this is due to the higher disease-
specific mortality (i.e., case fatality rate) of cervical cancer
compared to that of rotavirus gastroenteritis.
We found 5.2 lives were saved per 1,000 children vac-
cinated against rotavirus, and 12.6 lives were saved per
1000 pre-adolescent girls vaccinated against HPV 16,18.
The timing of the lives saved, however, drastically differs
since the deaths attributable to rotavirus occur in close
proximity to the acute infection, while deaths attributa-
ble to HPV-related cervical cancer occur in the girl’s
adult life largely after the age of 30.
Given this time difference of lives saved, when we
translated the health outcomes into DALYs averted
applying a 3% discount rate, the number of DALYs
averted was much higher with rotavirus vaccines com-
pared to HPV vaccines (~7.15 versus ~1.30 million).
Recently, arguments to use ‘slow discounting’ are made
on the basis of this large time effect when the health
outcome of an intervention is far in the future from the
time of the actual intervention [64].
When we used WHO’s cost-effectiveness threshold
based on GDP per capita, in most of the GAVI countries
(68 for rotavirus and 66 for HPV, at the cost of I$25 per
vaccinated individual) the incremental cost per DALY
averted was lower than each country’sG D Pp e rc a p i t a-
implying both vaccines would meet the criterion for
being “very cost-effective” [44,56,64].
We emphasize that our analysis was intended to provide
a broad comparative overview of the potential impact of
the rotavirus and HPV vaccines in the GAVI-eligible
countries, rather than to provide precise estimates of the
cost-effectiveness profiles of the two vaccines. The com-
parison is not based on empiric data obtained from a
head-to-head clinical trial where randomization can mini-
mize the risk of introducing bias caused by differences in
the two vaccination programs. Such clinical trials are
incredibly difficult to design when the comparison is
based on different populations and for different condi-
tions. Our cost-effectiveness results should be considered
preliminary since the composite costs for vaccine purchase
a n dd e l i v e r yw e r ea s s u m e dt ob et h es a m ef o rb o t hv a c -
cines and uniform across all GAVI-eligible countries, and
thus the differences in the cost-effectiveness results pri-
marily reflect the relative disease burden within and across
each of the GAVI countries. We therefore caution that
our base-case cost-effectiveness results should be
Table 3 Selected results of sensitivity analysis (Continued)
[r = 0%, K = 0] [0,71,1,0] [23,49,0,0]
[r = 3%, K = 0] (base-case) [0,68,4,0] [0,66,6,0]
[r = 0%, K = 1] [0,71,1,0] [23,49,0,0]
[r = 3%, K = 1] [0,68,4,0] [0,66,5,1]
Part (c): Scenario analysis (or multi-way sensitivity analysis) (Aggregated results across the GAVI-eligible countries)
Scenarios (defined by different combinations of different
values of the following parameters, with other parameter
values set at the base-case values):
- Vaccination costs, I$10, I$25, I$50
- Vaccine efficacy, 80%-/+20%
- Disease-specific mortality rates
No. of countries that belong to each of the cost-
effectiveness categories below
[cost-saving, very cost-effective, cost-effective, non-cost-
effective]
Scenario 1 (worst case)
- Vaccination costs: I$50
- Vaccine efficacy: 80% of base-case
- Mortality rates: 80% of base-case
[0,62,6,4] [0,40,25,7]
Scenario 2
- Vaccination costs: I$25
- Vaccine efficacy: 80% of base-case
- Mortality rates: 80% of base-case
[0,67,4,1] [0,60,10,2]
Scenario 3 (base-case)
- Vaccination costs: I$25
- Vaccine efficacy: base-case
- Mortality rates: base-case
[0,68,4,0] [0,66,6,0]
Scenario 4
- Vaccination costs: I$25
- Vaccine efficacy: 120% of base-case
- Mortality rates: 120% of base-case
[0,69,3,0] [1,69,2,0]
Scenario 5 (best case)
- Vaccination costs: I$10
- Vaccine efficacy: 120% of base-case
- Mortality rates: 120% of base-case
[5,67,0,0] [22,50,0,0]
r = discount rate, K = 0: uniform age weight, K = 1: non-uniform age weight. DALY = disability-adjusted life year.
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Page 12 of 17interpreted carefully. We suggest that, for priority setting
decisions at a country level, more rigorous comparisons
should be performed as country-specific data become
available. We hope our analysis would facilitate a more
specific discussion about important issues (as will be dis-
cussed later in this section) that should be considered in
setting priorities among different vaccination programs
competing for limited resources.
Other limitations of our analysis include the following:
First, our static models are not designed to capture
potential herd immunity effects that might result from
either vaccine intervention, thus likely underestimating
the true impact of the two vaccines. From a comparative
standpoint, our results do not reflect potential differ-
ences in level of herd immunity between the two vac-
cines, which in turn are dependent on multiple complex
factors (e.g., the nature of disease transmission and con-
tact pattern in a given setting) for each pathogen. Sec-
ond, when country-specific data were severely lacking,
our analysis relied on standardized assumptions that
may skew our estimates for both absolute and relative
vaccine benefits in different ways for each country. For
example, similar to the case of the composite vaccina-
tion program costs described previously, we relied on
standardized assumptions on medical utilization prac-
tices (e.g., one-time outpatient visit plus a 3-day admis-
sion for treating severe rotavirus gastroenteritis
requiring hospitalization) when calculating the costs to
treat diseases caused by the two pathogens in each
country. Third, due to the scarcity of relevant data on
rotavirus disease in older individuals, our rotavirus
model focuses on the disease burden among children
under age 5 with a time horizon of 5 years. While severe
rotavirus diseases occur primarily in younger children
and adult cases are usually not severe, it is known that
individuals older than 5 years may also develop sympto-
matic rotavirus diseases. Our study therefore presents a
likely, but moderate, underestimate of the health bene-
fits of rotavirus vaccination. Finally, we did not take into
account the potential impact of current supplementary
or alternative interventions (e.g., cervical cancer screen-
ing) on vaccine cost-effectiveness or the technological
changes that may affect the cost-effectiveness profiles of
the vaccines in the long-term.
Despite the limitations, the present comparative analy-
sis, coupled with our previously published analyses,
highlight some key factors related to the comparative
impact, affordability, cost-effectiveness, and distribu-
tional equity that decision-makers must consider when
introducing new interventions in resource-limited set-
tings. Moreover, the analysis provides insight into sev-
eral uncertainties that should be considered when
assessing these vaccines.
(a) Uncertainty about natural history, epidemiology, and
vaccine efficacy
Many aspects of the natural history of rotavirus and
HPV infection are still unknown, and there is still
uncertainty about the vaccines’ clinical effectiveness in
different settings. For example, for rotavirus, additional
research is needed to explore the nature of natural
immunity, the serotype distribution of rotavirus in local
settings, and long-term vacci n ee f f i c a c y[ 1 6 , 6 5 ] .F o r
HPV, in addition to uncertainty surrounding serotype
distribution by setting (and over time) as well as the
magnitude of cross protection, there are also uncertain-
ties about duration of immunity and age-specific efficacy
once sexual debut has occurred [4,60,66,67]. Vaccine
performance, as well as natural history of HPV, in boys
is less certain than in girls although information is being
collected. Thus, whether an HPV vaccination program
should also include boys has been a subject of much
discussion [32,36,61,66,68-70]. These issues may affect
the effectiveness, cost-effectiveness, and budgets of pro-
grams vaccinating against rotavirus or HPV. Accord-
ingly, as new clinical evidence from local settings
becomes available, re-evaluation of the vaccines in real-
world settings will be needed.
(b) Potential effects of different program costs
As previously discussed, it should be noted that our
comparative evaluation standardizes vaccination cost per
individual using a composite cost approach (i.e., set at
either I$10 or I$25 for all GAVI countries) [6,17]; this is
partly due to uncertainty about vaccine prices and coun-
try-specific program delivery costs associated with the
introduction of either vaccine and partly for ease of
comparison. Accordingly, the differences in the cost-
effectiveness profiles of rotavirus versus HPV vaccines
across the 72 GAVI countries stem mainly from the dif-
ferences in estimated disease burden and vaccine effi-
cacy adjusted for serotype distributions. It is of course
possible that the unit prices of the two different vaccines
may settle at different levels. In addition, because it is
likely to be harder to reach adolescent girls than infants,
the net costs for delivering the two vaccines may not be
similar within some countries; on the one hand, the cost
for delivering HPV vaccines could be higher, and on the
other delivery may be packaged with other health pro-
grams, directed towards adolescents, a country is priori-
tizing [4,64,71-73]. Both of these factors could influence
the prioritization of the two vaccines within a country
or across all GAVI countries. Given that our sensitivity
analyses show that the cost-effectiveness results of the
two vaccines were most sensitive to the cost per vacci-
nated child or girl, it would be crucial to re-evaluate the
vaccines’ economic impact as more local data on
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Page 13 of 17delivery costs become available through country-specific
data collection efforts [74,75].
(c) Herd immunity effects
A limitation of any static companion model used to
assess vaccine programs is the omission of indirect herd
immunity effects that may be realized after a large-scale
introduction of either rotavirus or HPV vaccination pro-
gram [37,64]. Yet it is notable that the extent of herd
immunity effects can vary between vaccines and across
settings, depending on the scale of interventions and
multiple other biological, epidemiological, and beha-
vioral factors. A recent study in the United States has
reported that a rotavirus vaccination program with 70%
coverage would reduce rotavirus infection prevalence by
an additional 15-25% due to herd immunity effects [57],
but another recent study in Kyrgyzstan has suggested
that the contribution of herd immunity effects to the
overall severe rotavirus disease burden reduction would
be minimal (~1%). Other studies have reported the
potential herd immunity effects due to HPV vaccination
would be more prominent [32,35,36,60-63]. Given that
t h e r eh a v eb e e nn onegative indirect effects (e.g., as
shown in the case of rubella vaccine due to a shift in
the age of onset of the disease) reported from either of
the vaccines, the explicit inclusion of any possible herd
immunity effects would presumably lead to more favor-
able cost-effectiveness results for both rotavirus and
HPV vaccines (though the extent may vary between the
two vaccines and across the countries).
(d) Discounting
As others have discussed, a constant discount rate may
underestimate the benefits of a health intervention in
which benefits are realized in the far distant future
when compared to an intervention where benefits occur
relatively soon after implementation [4,11,64,76,77]; our
comparative model-based evaluation of rotavirus versus
HPV vaccines illuminates this fact clearly. Our findings
show that, although the total number of averted deaths
following a single cohort would be very similar between
the two vaccines (~274,000 for rotavirus versus
~286,000 for HPV vaccines) under the base-case
assumptions, the numbers of undiscounted DALYs
averted substantially differ (~15.77 million for rotavirus
versus ~6.19 million for HPV vaccines) as a majority of
the deaths averted due to HPV vaccination would occur
at much older ages (after age 30). This discrepancy in
DALYs averted was even greater when we assumed a
3% discount rate; DALYs averted were significantly
reduced to ~7.15 million for rotavirus and ~1.30 million
for HPV vaccines, leading to a greater than 5-fold differ-
ence. Applying an alternative discounting technique
such as a slow discounting [64,76,77] to the evaluation
of HPV vaccines may lead to a more favorable cost-
effectiveness profile (of an already favorable profile) of
HPV vaccines. As we will discuss later, the choice of
discount rate may also be related to some ethical con-
cerns regarding whether and to what extent some lives
should be considered to have more value. Accordingly,
this study highlights the need for the use of alternative
discount rates even in a secondary analysis, as some pre-
vious studies [11,64,76,77] recommend.
(e) Population dynamics
In the standardized simulation for the GAVI countries,
we used population data projected by the UN Popula-
tion Prospects (The 2006 Revision) [38]. Among alterna-
tive projections, we chose to use the data that are based
on a medium fertility scenario, incorporate background
mortality, and are interpolated at 1-year intervals by age
and sex. The Prospects predicts various changes in
population structure over the next few decades. Most
relevantly, it assumes a rapidly increasing population
growth rate among adolescents and adults due to
decreased overall mortality paired with relatively slow
growth in new births in most developing countries (with
some exceptions) [38]. For example, if we follow the tra-
jectory of a cohort of 9-year-old girls during their life-
span, the sum of the numbers of women alive at each
age between ages 40-79 years–t h ea g eb a n dw h e r ea
majority of cervical cancer deaths occur–would be ~951
million in total for the 72 GAVI countries while the cor-
responding figure from the snapshot in 2010 is ~372
million. In contrast, the corresponding figures for the
population size of young children aged 0-4 years–the
relevant age band for rotavirus vaccines–are ~371 mil-
lion following the 2010 birth cohort and ~366 million
u s i n gt h es n a p s h o ti nt h es a m ey e a r .T h er e m a r k a b l e
increase of the age band 40-79 years explains in part the
gap between the recently observed total number of cer-
vical cancer deaths (~160,000; from a snapshot) and the
model projected figure (~560,000; from a trajectory
incorporating population dynamics) without HPV vacci-
nation in the GAVI countries. This suggests that, for
both vaccines, the magnitudes of the actual financial
requirements and reduction in disease burden might be
different from the values projected using the companion
model if actual population dynamics are different from
those projected by the version of population prospects
that we used.
In addition to efficiency issues and uncertainties in
disease burden and program costs, there are ethical as
well as political considerations, that may be relevant in
prioritizing new vaccine introduction in resource-poor
settings. In terms of potential ethical considerations, in
addition to distributional equity, our comparison of the
age-distribution of the health outcomes between
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level, a country’s decision to place priority on one vac-
cine over the other under limited resources may cause
public concerns of inter-generational equity. Further, at
the global level, given the regional distribution of the
health outcomes is different between the two vaccines
(i.e., rotavirus vaccines would avert a majority of deaths
in African settings while HPV vaccines would do so in
South Asian settings), prioritization of one vaccine over
the other may raise some inter-regional equity concerns.
Finally, since rotavirus vaccination provides direct bene-
fits to girls and boys, and right now HPV 16,18 vaccina-
tion would provide direct benefit to girls only (boys
would only benefit indirectly), there could be concerns
about gender equity that might be relevant to decision-
making. One purposeful goal of an exercise such as this
is to generate information that will stimulate a delibera-
tive dialogue among both decision makers and stake-
holders about just these very issues.
Political considerations will also be important to con-
sider in priority setting [78]. Although a full analysis
and discussion of the criteria is beyond the scope of this
article, it is crucial to recognize potential policy implica-
tions of taking into account different dimensions of cri-
teria when making decisions on which vaccines to
prioritize, not only for a comparison of rotavirus versus
HPV vaccines as illustrated here, but for a more com-
prehensive comparison including other new vaccines
such as pneumococcus. Recently there has been a
r e n e w e dc o m m i t m e n tt oh e l pl o c a lp o l i c ym a k e r sw i t h
priority setting and resource allocation, arguing for the
need for multi-criteria decision analysis [12,13,79].
Furthermore, when multiple new vaccines are assigned
priority in a country, it would be also important to con-
sider the implications of different timing or sequences
of vaccine introduction. For example, a new vaccine that
reduces early childhood mortality (e.g., rotavirus vac-
cine) may increase the impact of a subsequent vaccine
targeting adolescents (e.g., HPV vaccine) by increasing
the size of the target population for the latter vaccine.
This suggests the necessity of developing a more flexible
model that can capture population dynamics as well as
transmission dynamics for multiple vaccines of interest.
Conclusions
In conclusion, it would be desirable for policy makers to
be able to make decisions about the timing of new vac-
cine introduction using country-specific information,
taking into account various criteria that could affect
priority-setting procedures, and considering the impact
on other health sectors and systems [13,80-82]. While
avertable burden and cost-effectiveness are among these
criteria, other critical factors considered in decision
making and prioritization include (but are not limited
to) externalities, horizontal and generational equity, poli-
tical criteria, and affordability. Our findings show that
both rotavirus and HPV vaccines have potential to
reduce mortality and be cost-effective investments in
GAVI country settings, with very similar cost-effective-
ness profiles in terms of cost per DALY averted. How-
ever, we note that the absolute avertable burden will
vary with regional differences in disease-specific mortal-
ity, and that the comparative cost-effectiveness could
very well vary with country-specific differences in pro-
grammatic delivery costs and pricing, if markedly differ-
ent between the two vaccines. While the benefits of
these two new vaccines will be realized at different
times, the number of lives saved with these two vaccines
over each target populations’ lifetime will be quite simi-
lar. Our study illustrates that the use of comparable
models, consistent assumptions, and standardized out-
put that reports results similarly, allows for comparison
of the two new vaccines on different dimensions; this
approach can enrich the discussion about what attri-
butes might be weighted most prominently in the prior-
ity-setting process. Nevertheless, we re-emphasize that
our analysis was intended to provide an early insight on
what aspects of vaccine impact should be considered in
priority setting, using the examples of rotavirus versus
HPV vaccines in the GAVI-eligible countries. Accord-
ingly, for priority setting in an individual country, a
more comprehensive analysis should be performed, con-
sidering all relevant vaccination programs and using
country-specific data. In addition, given uncertainties
surrounding the epidemiology of the diseases, the vac-
cines’ target coverage, and the longer term vaccine
effects (e.g., herd immunity effects or serotype replace-
ment), iterative comparative evaluations will be prudent.
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